Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
TOKYO, April 1, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) annouced that Astellas and Viatris Pharmaceuticals Japan Inc. (Country Manager: Sun-A Kim, “Viatris”) have agreed to end the co-promotion of a hypercholesterolemia and familial hypercholesterolemia treatment (HMG-CoA reductase inhibitor) “Lipitor® Tablets 5mg, 10mg” (generic name: atorvastatin calcium hydrate, “Lipitor”) manufactured and sold by Astellas and co-promoted by both companies in Japan on July 31, 2021.
In accordance with this agreement, Viatris will solely promote and distribute Lipitor from August 1, 2021. Also, Viatris will take over the Marketing Authorization Holder of Lipitor from Astellas as of August 1, 2021.
The impact ot this transaction on Astellas’ financial results of the current fiscal year ending March 31, 2021, is expected to be minor.
Click below for a copy of the full press release
Follow us
